Digital An AI supercomputer and discovering next-gen brain disorder ... Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.